Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma

Severe ascites is an adverse event of ramucirumab (RAM), a second-line treatment for hepatocellular carcinoma (HCC). Ascites can be associated with various factors, including nutritional status and muscle quality. The aim of the present study was to investigate the prevalence and profiles of RAM-ass...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Mol Clin Oncol
Main Authors: Kamachi, Naoki, Shimose, Shigeo, Hirota, Keisuke, Koya, Shunji, Iwamoto, Hideki, Niizeki, Takashi, Shirono, Tomotake, Nakano, Masahito, Hashida, Ryuki, Kawaguchi, Takumi, Matuse, Hiroo, Noguchi, Kazunori, Koga, Hironori, Torimura, Takuji
Format: Artigo
Jezik:Inglês
Izdano: D.A. Spandidos 2021
Teme:
Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7947949/
https://ncbi.nlm.nih.gov/pubmed/33758660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2021.2241
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki